Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trialChigusa Morizane, Junji Furuse, Kazutoshi Tobimatsu et al.|Annals of Oncology|2019Cited by 333
Soluble MICA and a MICA Variation as Possible Prognostic Biomarkers for HBV-Induced Hepatocellular CarcinomaVinod Kumar, Koichi Matsuda, Paulisally Hau Yi Lo et al.|PLoS ONE|2012Cited by 94
A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC regionYuji Urabe, Koichi Matsuda, Hidenori Ochi et al.|Journal of Hepatology|2013Cited by 64
Interferon‑γ induced PD‑L1 expression and soluble PD‑L1 production in gastric cancerYushi Imai, Naoya Kato|Oncology Letters|2020Cited by 51
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinomaHiroaki Kanzaki, Naoya Kato|Scientific Reports|2021Cited by 39